Gilead Sciences specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (96.9%): for the treatment of HIV (86.6% of net sales), fungal infections (3.7%) and other (9.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- royalties (3%).
The remaining sales (0.1%) are from research and development services and from subcontracted production of therapeutic products.
Net sales break down geographically as follows: the United States (57.6%), Europe (34.4%) and other (8%).